TransMedics Group, Inc. (NASDAQ:TMDX) Receives $152.33 Consensus Price Target from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $152.3333.

A number of brokerages recently weighed in on TMDX. Stifel Nicolaus lifted their price objective on shares of TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a research note on Monday, March 9th. Needham & Company LLC lifted their price objective on shares of TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of TransMedics Group in a research note on Monday, March 16th. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, February 28th.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $116.11 on Monday. TransMedics Group has a fifty-two week low of $82.62 and a fifty-two week high of $156.00. The firm’s 50-day simple moving average is $122.74 and its 200 day simple moving average is $126.37. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. The stock has a market cap of $4.01 billion, a P/E ratio of 23.70 and a beta of 2.09.

Insider Activity

In related news, insider Anil P. Ranganath sold 864 shares of TransMedics Group stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $120,199.68. Following the transaction, the insider directly owned 13,091 shares of the company’s stock, valued at $1,821,219.92. The trade was a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Nicholas Corcoran sold 2,966 shares of TransMedics Group stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $412,629.92. Following the transaction, the insider directly owned 29,831 shares in the company, valued at approximately $4,150,088.72. The trade was a 9.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 16,205 shares of company stock valued at $2,353,002 over the last quarter. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TMDX. Whittier Trust Co. of Nevada Inc. grew its holdings in TransMedics Group by 981.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after acquiring an additional 206 shares during the period. Salomon & Ludwin LLC purchased a new position in TransMedics Group in the 3rd quarter worth about $28,000. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group in the 3rd quarter worth about $29,000. Optiver Holding B.V. increased its stake in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares in the last quarter. Finally, Allworth Financial LP increased its stake in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.